Literature DB >> 22670915

Prostate-cancer mortality after PSA screening.

Anthony V D'Amico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22670915     DOI： 10.1056/NEJMc1204298

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Clinical decisions. Screening for prostate cancer.

Authors:  Anthony V D'Amico; Matthew R Smith
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Authors:  Kubra Durkan; Zongrun Jiang; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Rajendra Prasad Bandari; Ashley F Szczodroski; Liqin Liu; Yubin Miao; Tamila Stott Reynolds; Charles J Smith
Journal:  Nucl Med Biol       Date:  2013-11-28       Impact factor: 2.408

Review 3.  Meeting the global demands of epidemiologic transition - the indispensable role of cancer prevention.

Authors:  Silvia Franceschi; Christopher P Wild
Journal:  Mol Oncol       Date:  2012-11-17       Impact factor: 6.603

4.  PSA screening for prostate cancer: why so much controversy?

Authors:  Fernand Labrie
Journal:  Asian J Androl       Date:  2013-06-17       Impact factor: 3.285

5.  Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).

Authors:  Carsten Stephan; Harry Rittenhouse; Xinhai Hu; Henning Cammann; Klaus Jung
Journal:  EJIFCC       Date:  2014-04-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.